{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-003776","form_type":"8-K","ticker":"GLUE","cik":"0001826457","company_name":"Monte Rosa Therapeutics, Inc.","filed_at":"2025-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.109233+00:00","generated_at":"2026-05-28T05:32:07.664826+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Monte Rosa announces 2025 milestones and $377M cash position funding into 2028","bullets":["Preliminary cash, equivalents, and securities of $377.0M as of Dec 31, 2024; funds operations into 2028.","Initial Phase 1 SAD/MAD data for VAV1 degrader MRT-6160 expected Q1 2025; Novartis license deal gave $150M upfront.","Updated biomarker and activity data from MRT-2359 Phase 1/2 in MYC-driven solid tumors expected Q1 2025.","IND filing for NEK7 degrader MRT-8102 in H1 2025; CDK2 candidate nomination in H1 2025.","Second-generation NEK7 candidate with CNS penetration nomination in H2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-003776","json":"https://secwatch.observer/filing/0000950170-25-003776.json","markdown":"https://secwatch.observer/filing/0000950170-25-003776.md","text":"https://secwatch.observer/filing/0000950170-25-003776.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826457/000095017025003776/0000950170-25-003776-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826457/000095017025003776/glue-20250110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T05:32:07.664826+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}